Opinion|Videos|February 24, 2025
Strategies for Determining Severity of Atopic Dermatitis
Panelists discuss how atopic dermatitis severity classification relies on multiple assessment tools including EASI, SCORAD, POEM, and BSA measurements. Special attention is given to sensitive areas (hands, feet, genitals) as they significantly impact quality of life. Disease extent, intensity of symptoms, and functional impairment guide categorization into mild, moderate, or severe cases.
Advertisement
Episodes in this series
Video content above in prompted by the following:
- What are the criteria for classifying atopic dermatitis as mild, moderate, or severe?
- Do you use NRS, EASI, SCORAD, POEM, BSA, or other methods?
- How important is it that problem areas (such as the hands, feet, or genitals) are emphasized in the assessment for disease severity and impact on the patient?
Advertisement
Related to this article
KT-621, an oral STAT6 degrader, cut mean EASI by 62.6% after 4 weeks with no treatment-related adverse events in a phase 1b atopic dermatitis study.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
In the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks.
Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.
Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.
Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.
Phase 2 ENHANCE and ENRICH data show BRII-179 plus elebsiran and peginterferon increased HBsAg loss in chronic HBV, with priming halving peginterferon use.
Pooled phase 2 data show fazirsiran 200 mg cut intrahepatic Z-AAT by about 90% vs placebo in AATD liver disease, with stable lung function through the OLE.
Advertisement
Advertisement
Trending on HCPLive
1
2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics
2
Noninvasive Models Underestimate CSPH in MASH Cirrhosis vs HVPG
3
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
4
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
5